Esmolol for the Treatment of Hypertension After Intracerebral Hemorrhage Study (ETHICHS)

Summary

Because of its pharmacokinetic characteristics, such as short half-life and its safety profile, esmolol hydrochloride is a beta blocker suitable for venous use in the form of continuous infusion. Strategies that improve the blood pressure control of patients with hemorrhagic stroke during the first hours of hospitalization are determinant in controlling the hematoma expansion and determining factor in its prognosis. This study was designed with the objective of evaluating the beneficial effects of combining esmolol hydrochloride with sodium nitroprusside for the blood pressure control of participants with hemorrhagic stroke.

Timeline

Start

2019-04-18

Primary completion

2021-10-31

Completion

2021-10-31

Drugs

Indications